News about "Lupin"

Lupin Secures EMA Approval for Expanded NaMuscla Pediatric Use

Lupin has received EMA approval to expand the pediatric indication of NaMuscla, including two new capsule strengths of 62 mg and 83 mg.

Lupin | 03/07/2026 | By News Bureau |  323

Lupin Launches Azilsartan Medoxomil Tablets in US

Lupin has launched Azilsartan Medoxomil Tablets in the US, a bioequivalent generic version of Edarbi, indicated for the treatment of hypertension in adults.

Lupin | 17/06/2026 | By News Bureau

Lupin Partners with ERN to Launch Luforbec in Spain

Lupin has partnered with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain, combining Lupin’s respiratory expertise and advanced inhaler manufacturing capabilities with ERN’s strong market presence to expand access to high-quality respiratory care for patients across the country.

Lupin | 08/06/2026 | By News Bureau

Lupin Receives US FDA Approval for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets

Lupin has received US FDA approval for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, a bioequivalent to Reference Listed Drug (RLD) Sutab Tablets of Azurity Pharmaceuticals.

Lupin | 02/06/2026 | By News Bureau

Lupin Receives US FDA EIR for Ankleshwar Manufacturing Facility

Lupin has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Ankleshwar facility following the successful closure of a product-specific pre-approval inspection conducted in March 2026.

Lupin | 28/05/2026 | By News Bureau |  142

Lupin Secures China Approval for Oseltamivir Phosphate Oral Suspension

Lupin receives approval in China for Oseltamivir Phosphate Oral Suspension 6 mg/mL, expanding access to influenza treatment, particularly for pediatric patients.

Lupin | 25/05/2026 | By News Bureau |  107

Lupin Gets US FDA Tentative Approval for Revefenacin Inhalation Solution

Lupin receives tentative US Food and Drug Administration (FDA) approval for Revefenacin Inhalation Solution, a generic version of Yupelri for maintenance treatment of Chronic
Obstructive Pulmonary Disease (COPD).<br />

Lupin | 20/05/2026 | By News Bureau

Lupin Secures FDA Approval for Famotidine Injection USP

Lupin has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Famotidine injection USP, 20 mg/2 mL (10 mg/mL), single-dose vials.

Lupin | 14/05/2026 | By News Bureau |  153

Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid

Lupin secures US Food and Drug Administration (FDA) approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), bioequivalent to Ravicti Oral Liquid.

Lupin | 05/05/2026 | By News Bureau |  109

Lupin Subsidiary Settles US Antitrust Case with Humana

Lupin subsidiary Lupin Pharmaceuticals Inc has reached a USD 30 million settlement with Humana in a US antitrust case, resolving claims without any admission of liability.

Lupin | 17/04/2026 | By News Bureau |  126